RSS   Newsletter   Contact   Advertise with us

Soligenix revenues $4.6 million

Share on Twitter Share on LinkedIn
Christian Fernsby ▼ | March 31, 2020
Soligenix announced its financial results for the year ended December 31, 2019.
Soligenix
Soligenix   Basic net loss was $9.4 million, or ($0.48) per share
Soligenix's revenues for the year ended December 31, 2019 were $4.6 million as compared to $5.2 million for the year ended December 31, 2018.

Topics: Soligenix

Revenues included payments on a contract in support of RiVax, in addition to the grants received to support the development of SGX301 for the treatment of CTCL and SGX942 for the treatment of oral mucositis in HNC.

Soligenix's basic net loss was $9.4 million, or ($0.48) per share, for the year ended December 31, 2019, as compared to $8.9 million, or ($0.68) per share, for the year ended December 31, 2018.

Research and development expenses were $8.1 million as compared to $6.8 million for the years ended December 31, 2019 and 2018, respectively.

The increase in research and development spending for the year ended December 31, 2019 was primarily attributable to the expansion of the Phase 3 clinical trial of SGX942 as well as the ongoing Phase 3 clinical trial of SGX301, compared to the same period in 2018.

General and administrative expenses were $3.4 million as compared to $3.0 million for the years ended December 31, 2019 and 2018, respectively.

As of December 31, 2019, the Company's cash position was approximately $5.4 million.


 

MORE INSIDE POST